SEP 06, 2017 09:00 AM PDT
WEBINAR: Manufacturing and characterization of therapeutic exosomes for clinical studies
SPONSORED BY: Miltenyi Biotec
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
8 7 1636

Speakers:
  • Head of Analytical Development, Capricor Therapeutics Inc.
    Biography
      My PhD work investigated the mechanisms of RNA editing, directed by small RNA guides, in conjunction with the RNA polymerase machinery. I expanded my training in RNA synthesis and transcription regulation with a postdoctoral fellowship at Stanford University. There I studied chromatin structural elements that directed repression, enhancement and insulation of transcription using dozens of transgenic mouse models. My first industry appointment was with the high-throughput mouse gene knockout company, Deltagen, Inc, where I managed the Gene Expression group responsible for characterizing the transcriptome changes in knockout mouse models. I designed hundreds of TaqMan-based qPCR assays and ran those across 20 different tissues from mice to provide customers with comprehensive gene expression data. In 2006 I joined System Biosciences, a Clontech company, where I have been the PI on 3 independent SBIR grants that led to popular research products that have become standard in the study of microRNAs and extracellular vesicle (exosome) analysis. As Senior Director of product development at System Biosciences (SBI) until February 2016, I led SBI's scientific staff of top-level PhD researchers innovating new technologies, validating their functions and applications, and then ultimately bringing them to market as successful products for life science researchers. In 2016, I joined the faculty at Cedars-Sinai Heart Institute as an Associate Professor and also became the Head of Analytical Development for Capricor Therapeutics Inc. My current research involves the characterization and development of therapeutic exosomes for a variety of disease applications. The goals are to better understand the principal therapeutic agents associated with these exosomes and how to engineer their cargo for enhanced therapeutic potency.

    Abstract:

    DATE: September 6, 2017
    TIME: 9:00AM PST, 12:00PM ET

     

    The era of using extracellular vesicles (EVs) and exosomes for regenerative medicine applications in the clinic is here. We utilize a unique cardiosphere-derived stem-like cell culturing process to manufacture their secreted EVs present in the conditioned medium in large batches for pre-clinical animal studies. This webinar will review the strategies for clinical scale EV manufacturing, characterization of surface phenotypes and RNA cargo, as well as building a pipeline for successful QC of these EVs for use in the clinic.

    Learning Objectives:

    • What are extracellular vesicles and exosomes?     
    • What molecular tools are available to characterize extracellular vesicles?
    • How are extracellular vesicles manufactured for use in clinical studies?

     

    “The content of the following presentation by Dr. Travis Antes, has not been prepared by, interpreted by or reviewed by Miltenyi Biotec Inc. The views and opinions expressed in the following presentation are solely those of the investigator. All Miltenyi Biotec Inc.’s products discussed herein are for Research Use Only unless otherwise specified.”

     


    Show Resources
    Loading Comments...